Sugi Predict

Sugi Predict / Compounds / SCHEMBL3535294

SCHEMBL3535294

SCHEMBL3535294

c1cnc2[nH]c(-c3n[nH]c4ccccc34)nc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 6/20 0.68
▸ FLT1 P17948 6/20 0.68
▸ PDPK1 O15530 4/20 0.54
▸ ITK Q08881 3/20 0.54
▸ CLK2 P49760 2/20 0.52
▸ DYRK1A Q13627 2/20 0.52
▸ WNT1 P04628 2/20 0.52
▸ TGFBR1 P36897 1/20 0.52
▸ CLK3 P49761 1/20 0.52
▸ LRRK2 Q5S007 2/20 0.51
▸ CHEK1 O14757 3/20 0.51
▸ JAK2 O60674 2/20 0.51
▸ CDK2 P24941 2/20 0.51
▸ TYK2 P29597 2/20 0.51
▸ JAK3 P52333 2/20 0.51
▸ PLK4 O00444 1/20 0.51
▸ AURKA O14965 1/20 0.51
▸ CHUK O15111 1/20 0.51
▸ ROCK2 O75116 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29714871 1.00 FGFR1 (0.68) FGFR1FLT1PDPK1ITKCLK2
SCHEMBL17557500 0.87 FGFR1 (0.49) FGFR1FLT1PDPK1ITKCLK2
SCHEMBL29384149 0.87 FGFR1 (0.49) FGFR1FLT1PDPK1ITKCLK2
SCHEMBL29833911 0.86 CLK2 (0.53) FGFR1FLT1PDPK1ITKCLK2
SCHEMBL17555609 0.86 CLK2 (0.53) FGFR1FLT1PDPK1ITKCLK2
SCHEMBL29714868 0.84 ITK (0.52) FGFR1FLT1PDPK1ITKCLK2
SCHEMBL18426861 0.84 ITK (0.52) FGFR1FLT1PDPK1ITKCLK2
SCHEMBL4038255 0.83 FGFR1 (0.68) FGFR1FLT1PDPK1ITKCLK2
SCHEMBL17594418 0.82 WNT1 (0.51) FGFR1FLT1PDPK1CLK2DYRK1A
SCHEMBL311148 0.82 FGFR1 (1.00) FGFR1FLT1PDPK1ITKCLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 — — US claimed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US claimed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 — — EP claimed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US claimed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 — — WO claimed
US-12582781-B2 Injection systems and methods of their use MeiraGTx Ocular UK Limited (GB) 2026-03-24 — — US disclosed
US-20240197523-A1 MOTORIZED INJECTION SYSTEM AND METHODS OF USE MEIRAGTX UK II LIMITED (GB) 2024-06-20 — — US disclosed
US-20220379044-A1 Injection Systems and Methods of Their Use MEIRAGTX THERAPEUTICS, INC. (US) 2022-12-01 — — US disclosed
CN-114728132-A Injection system and method of use 梅拉格特克斯治疗学股份有限公司 2022-07-08 — — CN disclosed
US-10280166-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-05-07 — — US disclosed
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2019-02-21 — — US disclosed
US-10023572-B2 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-07-17 — — US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 — — US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 — — US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 — — US disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 — — US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 — — EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 FGFR1 583/4885FLT1 2074/4885PDPK1 291/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A FGFR1 254/4885FLT1 1117/4885PDPK1 216/4885
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885PDPK1 1862/4885
US-12582781-B2 Injection systems and methods of their use GJA1, MMP1, LNPK FGFR1 3075/4885FLT1 345/4885PDPK1 4151/4885
US-10280166-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A FGFR1 40/4885FLT1 131/4885PDPK1 149/4885
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A FGFR1 40/4885FLT1 131/4885PDPK1 149/4885
US-10023572-B2 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A FGFR1 40/4885FLT1 131/4885PDPK1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.